Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Bought by Trexquant Investment LP

Trexquant Investment LP grew its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 27.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 203,571 shares of the company's stock after purchasing an additional 43,947 shares during the quarter. Trexquant Investment LP owned approximately 0.73% of Castle Biosciences worth $5,425,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Wellington Management Group LLP bought a new position in shares of Castle Biosciences in the 4th quarter valued at about $19,244,000. Point72 Asset Management L.P. grew its holdings in Castle Biosciences by 828.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 499,192 shares of the company's stock worth $14,237,000 after acquiring an additional 445,415 shares in the last quarter. Vanguard Group Inc. increased its holdings in Castle Biosciences by 4.8% during the fourth quarter. Vanguard Group Inc. now owns 1,832,535 shares of the company's stock valued at $48,837,000 after buying an additional 83,783 shares during the period. Hussman Strategic Advisors Inc. bought a new stake in Castle Biosciences during the fourth quarter valued at about $1,959,000. Finally, State Street Corp lifted its position in Castle Biosciences by 9.8% during the third quarter. State Street Corp now owns 680,001 shares of the company's stock valued at $19,394,000 after acquiring an additional 60,924 shares during the last quarter. 92.60% of the stock is owned by institutional investors.

Insider Activity

In other Castle Biosciences news, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total transaction of $221,613.39. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Derek J. Maetzold sold 986 shares of the company's stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $28.03, for a total value of $27,637.58. Following the sale, the insider now owns 80,818 shares in the company, valued at approximately $2,265,328.54. This trade represents a 1.21 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 34,858 shares of company stock valued at $771,416. 7.20% of the stock is currently owned by insiders.

Castle Biosciences Price Performance

CSTL stock traded down $1.12 during mid-day trading on Thursday, reaching $19.00. The company's stock had a trading volume of 62,117 shares, compared to its average volume of 374,528. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. The company's 50 day moving average is $22.70 and its two-hundred day moving average is $27.23. The stock has a market cap of $547.80 million, a PE ratio of 94.93 and a beta of 1.11. Castle Biosciences, Inc. has a fifty-two week low of $16.97 and a fifty-two week high of $35.84.

Analyst Ratings Changes

A number of analysts recently commented on CSTL shares. Stephens reiterated an "overweight" rating and issued a $41.00 target price on shares of Castle Biosciences in a research note on Thursday, January 2nd. Guggenheim set a $30.00 price objective on Castle Biosciences and gave the company a "buy" rating in a report on Friday, March 28th. Finally, Robert W. Baird upped their price objective on shares of Castle Biosciences from $36.00 to $37.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $38.75.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.